- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT02243592
Molekuláris profilalkotás olyan rákos betegek szövetmintáiban, akik kivételesen reagálnak a kezelésre
Kivételes válaszadók Kísérleti Tanulmány: A kivételesen reagáló rákos betegek daganatainak molekuláris profilozása
This pilot research trial studies molecular profiling in tissue samples from patients with cancer who got better with treatment that didn't work for most other patients with the same disease. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to how well patients respond to treatment.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
PRIMARY OBJECTIVES:
I. To identify molecular indicators in malignant tissues from patients who were exceptional responders on clinical trials or standard systemic treatments using whole exome and/or targeted deep sequencing, as well as potentially other sequencing and other molecular characterization methods (if adequate tissue exists).
II. To explore associations between the identified molecular indicators and the putative mechanism of action of the treatment received by the patient.
III. To test the feasibility of identifying "exceptional responders", obtaining the relevant tumor and normal tissue and clinical data, and performing whole exome and/or targeted deep sequencing on these samples.
OUTLINE:
Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted next generation sequencing (NGS) assay deep sequencing. Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, messenger ribonucleic acid (RNA) (mRNA)-sequencing, micro (miRNA) sequencing, promoter methylation analysis, and single nucleotide polymorphism (SNP) analysis.
Tanulmány típusa
Beiratkozás (Tényleges)
Kapcsolatok és helyek
Tanulmányi helyek
-
-
California
-
Duarte, California, Egyesült Államok, 91010
- City of Hope Comprehensive Cancer Center
-
Fresno, California, Egyesült Államok, 93720
- Kaiser Permanente-Fresno
-
Oakland, California, Egyesült Államok, 94611
- Kaiser Permanente-Oakland
-
Richmond, California, Egyesült Államok, 94801
- Kaiser Permanente-Richmond
-
San Francisco, California, Egyesült Államok, 94158
- UCSF Medical Center-Mission Bay
-
Santa Clara, California, Egyesült Államok, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa, California, Egyesült Államok, 95403
- Kaiser Permanente-Santa Rosa
-
Stockton, California, Egyesült Államok, 95210
- Kaiser Permanente-Stockton
-
Walnut Creek, California, Egyesült Államok, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Egyesült Államok, 80045
- UCHealth University of Colorado Hospital
-
Fort Collins, Colorado, Egyesült Államok, 80524
- Poudre Valley Hospital
-
-
Connecticut
-
Greenwich, Connecticut, Egyesült Államok, 06830
- Greenwich Hospital
-
-
Delaware
-
Newark, Delaware, Egyesült Államok, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Egyesült Államok, 19713
- Medical Oncology Hematology Consultants PA
-
-
District of Columbia
-
Washington D.C., District of Columbia, Egyesült Államok, 20016
- Sibley Memorial Hospital
-
-
Georgia
-
Atlanta, Georgia, Egyesült Államok, 30322
- Emory University Hospital/Winship Cancer Institute
-
Columbus, Georgia, Egyesült Államok, 31904
- John B Amos Cancer Center
-
Valdosta, Georgia, Egyesült Államok, 31602
- South Georgia Medical Center/Pearlman Cancer Center
-
-
Idaho
-
Boise, Idaho, Egyesült Államok, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
-
Illinois
-
Chicago, Illinois, Egyesült Államok, 60631
- Presence Resurrection Medical Center
-
Chicago, Illinois, Egyesült Államok, 60612
- Rush MD Anderson Cancer Center
-
Decatur, Illinois, Egyesült Államok, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Egyesült Államok, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Evanston, Illinois, Egyesült Államok, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Peoria, Illinois, Egyesült Államok, 61615
- Illinois CancerCare-Peoria
-
Springfield, Illinois, Egyesült Államok, 62702
- Springfield Clinic
-
-
Iowa
-
Cedar Rapids, Iowa, Egyesült Államok, 52402
- Physicians' Clinic of Iowa PC
-
-
Maine
-
York Village, Maine, Egyesült Államok, 03909
- York Hospital
-
-
Maryland
-
Bethesda, Maryland, Egyesült Államok, 20892
- NCI - Center for Cancer Research
-
Bethesda, Maryland, Egyesült Államok, 20892
- National Cancer Institute Developmental Therapeutics Clinic
-
-
Michigan
-
Ann Arbor, Michigan, Egyesült Államok, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Egyesült Államok, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Egyesült Államok, 48114
- Trinity Health Medical Center - Brighton
-
Detroit, Michigan, Egyesült Államok, 48201
- Wayne State University/Karmanos Cancer Institute
-
Grand Rapids, Michigan, Egyesült Államok, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Marquette, Michigan, Egyesült Államok, 49855
- UP Health System Marquette
-
Marquette, Michigan, Egyesült Államok, 49855
- UP Health System Hematology Oncology Marquette
-
Southfield, Michigan, Egyesült Államok, 48075
- Henry Ford Health Providence Southfield Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Egyesült Államok, 63703
- Saint Francis Medical Center
-
Springfield, Missouri, Egyesült Államok, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Egyesült Államok, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Egyesült Államok, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Egyesült Államok, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Egyesült Államok, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Great Falls, Montana, Egyesült Államok, 59405
- Benefis Sletten Cancer Institute
-
-
New Hampshire
-
Portsmouth, New Hampshire, Egyesült Államok, 03802
- Portsmouth Regional Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, Egyesült Államok, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Rochester, New York, Egyesült Államok, 14642
- University of Rochester
-
-
North Carolina
-
Durham, North Carolina, Egyesült Államok, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, Egyesült Államok, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Egyesült Államok, 58122
- Sanford Roger Maris Cancer Center
-
-
Ohio
-
Columbus, Ohio, Egyesült Államok, 43214
- Riverside Methodist Hospital
-
-
Oklahoma
-
Lawton, Oklahoma, Egyesült Államok, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Egyesült Államok, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Egyesült Államok, 97227
- Kaiser Permanente Northwest
-
-
Pennsylvania
-
Phoenixville, Pennsylvania, Egyesült Államok, 19460
- Reading Hospital McGlinn Cancer Institute at Phoenixville
-
West Chester, Pennsylvania, Egyesült Államok, 19380
- Chester County Hospital
-
West Reading, Pennsylvania, Egyesült Államok, 19611
- Reading Hospital
-
-
South Carolina
-
Greenville, South Carolina, Egyesült Államok, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Egyesült Államok, 29605
- Prisma Health Cancer Institute - Butternut
-
Seneca, South Carolina, Egyesült Államok, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Sioux Falls, South Dakota, Egyesült Államok, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Egyesült Államok, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Kingsport, Tennessee, Egyesült Államok, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
-
Texas
-
Houston, Texas, Egyesült Államok, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Houston, Texas, Egyesült Államok, 77030
- Ben Taub General Hospital
-
San Antonio, Texas, Egyesült Államok, 78229
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
Salt Lake City, Utah, Egyesült Államok, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Virginia
-
Charlottesville, Virginia, Egyesült Államok, 22908
- University of Virginia Cancer Center
-
-
West Virginia
-
Martinsburg, West Virginia, Egyesült Államok, 25401
- WVUH-Berkely Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, Egyesült Államok, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Summit, Wisconsin, Egyesült Államok, 53066
- Aurora Medical Center in Summit
-
Waukesha, Wisconsin, Egyesült Államok, 53188
- UW Cancer Center at ProHealth Care
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Mintavételi módszer
Tanulmányi populáció
Patients with cancer participating in the Exceptional Cases Initiative
Leírás
Inclusion Criteria:
-
Documented exceptional response, defined as patients meeting the following criteria:
-
Complete response to a regimen in which complete response is expected in < 10% of similarly treated patients
-
Partial response (PR) > 6 months in a regimen in which PRs > 6 months are expected in < 10% of patients with similar disease treated with same or similar regimen
-
Complete response (CR) or PR of unusual duration, such that the internal review committee considers it to be an exceptional response; examples below:
- PR of duration > 3 x the median expected PR duration (in cases where PR is expected in > 10% of patients with the same disease treated with the same regimen)
- CR or duration > 3 x the median expected CR duration (in cases where CR may be seen in > 10% of patients with same disease treated with same regimen)
- The observed duration of CR (or PR) is longer than expected for 90% of patients with same disease treated with same regimen
-
Note: it is not required that the patient be enrolled on a clinical trial when the exceptional response was observed
-
-
Reports of radiologic scans or other evidence documenting response will be submitted for review; cases where response is not assessable (e.g. adjuvant treatment) will not be eligible because the outcome can not be attributed to a specific treatment
-
Treatment history must be available, for prior treatment and for the drug to which the exceptional response occurred
-
Patient must meet consent criteria; this requires: (i) current exceptional responder (ER) consent by a living participant not lost to follow-up, (ii) prior consent for future research by a participant not known to be deceased, but lost to follow-up, or (iii) if patient is deceased and did not decline to participate in research at the time of tissue removal for any tissue that would be used in this study, then no consent is required
-
Tumor sample available that meets study requirements
-
Required tumor samples MUST exist and be able to be submitted; investigators wishing to submit samples must not have made agreements that would prohibit the free use of data from such samples; the National Cancer Institute (NCI) will provide investigators with a letter for the collaborator amending their existing agreement to allow for the case to be submitted
- Tumor tissue from prior to administration of the drug to which the exceptional response occurred is required; ideally this sample will have been collected just prior to treatment, but other prior tissue will be considered; tissue may be fresh frozen or formalin-fixed paraffin embedded
- Tumor tissue amount must be at least a core biopsy, and meet minimum specimen requirements
-
Encouraged: normal tissue sample: (optional): blood or other specimen source for germline sequencing
-
The tumor samples and clinical data submitted to the Exceptional Responders Database in database in Genotypes and Phenotypes (dbGaP) will need to have appropriate agreements in place to allow for the submission; the Exceptional Responders Database can accept clinical data and samples from cases enrolled on a Cancer Therapy Evaluation Program (CTEP) sponsored clinical trial and cases that were not enrolled on any clinical trial; if the response occurred on a trial that was not CTEP-sponsored, there are existing agreements between the submitting site and the pharmaceutical company; if existing agreements do not allow for the submission of sample and clinical data, the NCI will provide the investigators with a letter that allows the tissue to be used for the exceptional responders study if signed by the appropriate collaborator; the letter modifies the existing agreement to include the CTEP Intellectual Property (IP) Option language that would allow the case to be submitted to the Exceptional Responders Database; if the existing agreement cannot be modified and the letter cannot be signed, the proposed case will not be accepted; Note: as stated above, the patient does not need to have been enrolled on a clinical trial to be eligible for the exceptional responders study
Exclusion Criteria:
- Patient's response did not meet criteria for an exceptional response
- Patient's treatment regimen is expected to lead to CR or durable PR in > 10% of patients
- Patient's duration of response is not > 3 x expected median length of response
- Response not evaluable or not able to be attributed to systemic treatment (e.g. adjuvant treatment)
- Patient refused consent for use of tissue for research activities included in the exceptional responders study
- Tumor sample from prior to the exceptional response is not available, or does not meet quality metrics
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Megfigyelési modellek: CASE_CONTROL
- Időperspektívák: RETROSPECTIVE
Kohorszok és beavatkozások
Csoport / Kohorsz |
Beavatkozás / kezelés |
|---|---|
|
Ancillary-Correlative (molecular profiling)
Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted NGS assay deep sequencing. Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, mRNA-sequencing, miRNA sequencing, promoter methylation analysis, and SNP analysis. |
Undergo sequencing and SNP analysis |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Molecular features in tissue samples from patients who were exceptional responders
Időkeret: Baseline
|
The molecular features of the tumors in the patients will be discernible as distinct to the tumor by comparison to (i) samples from normal tissue in the same patient and (ii) databases of similar data for normal and other tumor types. |
Baseline
|
|
Putative mechanisms of action of the treatments that the patients received when they experienced their exceptional responses
Időkeret: Baseline
|
The associations between identified molecular features and the putative mechanisms of action of the treatments that the patients received when they experienced their exceptional responses will be explored. Statistical analyses will be primarily descriptive. |
Baseline
|
|
Number of cases identified as potential exceptional responders
Időkeret: Baseline
|
Statistical analyses will be primarily descriptive. |
Baseline
|
|
Percentage of identified potential cases confirmed to be exceptional responders
Időkeret: Baseline
|
Statistical analyses will be primarily descriptive. |
Baseline
|
|
Percentage of confirmed exceptional responders for which adequate tissue with appropriate informed consent is acquired
Időkeret: Baseline
|
Statistical analyses will be primarily descriptive. |
Baseline
|
|
Percentage of acquired cases with tissue for which at least the minimum molecular characterization is successfully obtained
Időkeret: Baseline
|
Statistical analyses will be primarily descriptive. |
Baseline
|
|
Percentage of molecularly characterized cases for which a Molecular Characterization report identified (without reference to the drug received by the patient) at least one feature judged to have potential therapeutic relevance
Időkeret: Baseline
|
Promising discoveries will be summarized for the group of cases for which the minimum molecular characterization was successfully obtained. For each such case, molecular data will be reviewed by an expert panel ("Panel") to identify interesting features. All estimated proportions will be accompanied by exact 95% confidence intervals. |
Baseline
|
|
Percentage of cases with >= 1 feature on Molecular Characterization report that was judged to have potential therapeutic relevance to the specific class of drug the patient actually received when the exceptional response was experienced
Időkeret: Baseline
|
Promising discoveries will be summarized for the group of cases for which the minimum molecular characterization was successfully obtained. For each such case, molecular data will be reviewed by the Panel to identify interesting features. All estimated proportions will be accompanied by exact 95% confidence intervals. |
Baseline
|
|
Percentage of cases with >= 1 feature that correlates with the mechanism of action of the specific grant to which the exceptional response occurred that was found after further analyzing the molecular profile data for relevant molecular abnormalities
Időkeret: Baseline
|
Promising discoveries will be summarized for the group of cases for which the minimum molecular characterization was successfully obtained. For each such case, molecular data will be reviewed by the Panel to identify interesting features. All estimated proportions will be accompanied by exact 95% confidence intervals. |
Baseline
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Kutatásvezető: S. P Ivy, National Cancer Institute (NCI)
Publikációk és hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becsült)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- NCI-2014-01585
- UM1CA186704 (Az Egyesült Államok NIH támogatása/szerződése)
- 9671 (Egyéb azonosító: CTEP)
- NCI-2014-01585 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 9671 (Egyéb azonosító: National Cancer Institute)
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .